



The importance of Air Log 6 as first defense.

The need to contain the COVID-19 pandemic through the development of technologies to respond to the SARS-CoV-2 infection is urgent.

An extremely important aspect is the study on immunity induced by SARS-CoV-2 on hospitalized patients in critical condition. Of note is the observation that the most severe cases of SARS-CoV-2 present an excessive immune response. Therefore it was decided to plan a system to limit and contain this immune storm responsible for serious molecular diseases

Air Log 6 prevention of "molecular pathologies"

The following clinical action of Air Log 6 was also identified in molecular pathologies caused by COVID-19, i.e. the containment of the neuroinvasion responsible for retrograde axonal damage.

Of note is the observation that the most severe cases of COVID-19 present an excessive immune response, composed by lymphopenia, eosinopenia, activation of cells, activation of cytokine-secreting cells and the consequent cytokine storm, resulting in acute respiratory distress syndrome (ARDS) with tissue damage, disseminated intravascular coagulation and multiorgan collapse. In addition to the cytokine storm, the increase in HLA class II proteins and HLA-DR expressed on the surface of monocytes, when the HLA-DR value decreases, pneumonia leads to severe respiratory collapse with alteration of IL6 lymphocytes, in fact a collapse of the blood profile because there is a negative correlation. The action of the aerosolized antiseptic Airlog 6 counteracts these alterations thanks to its presence in the tissues that absorb micro-amounts of protective aerosol.

CH.I.S.S. S.R.L.

Sede legale Piazza San Pietro in Vincoli 10 – 00184 Roma (RM)
Sede operativa Via Flaminia Ternana, 446 - 05035 Narni (TR)
Unità locale Via Giovanni Durando 38 – 20158 Milano (MI)

info@chiss.it - ww.chiss.it



In fact, the benefits are many, we only mention a brief concise description of the beneficial clinical action of Air Log 6:

- It limits and contains the cytokine storm
- It contrasts the alterations of human HLA and HLA-DR
- It mediates the SARS-CoV-2 of the lymphocytes T cell response (protective immunity)
- It limits immune system deregulation in COVID-19, reducing the risk of lymphopenia and eosinopenia
- The containment of the antibody response that in COVID-19 has shown a persistence of viral RNA positivity even in cases of mild disease. In the most severe forms, the antibody response is excessive with a titer of 3000 times higher which must certainly be contained.

The continuous and permanent presence of an air neutralizing agent with antiseptic action brings an important limitation to the deregulation of the immune system, that in short it manifests itself with an elevation of cytokine IL6 which reduces monocytes CD14 + and lymphocytes in a negative feedback circuit, because CD14 + monocytes and lymphocytes are the major producers of IL6 in COVID19 patients. The amount of the viral load is important in determining the severity of the disease, against which, however, the body is able to induce a humoral and immediate response of T cells in a robust manner. Therefore an aerosol capable of reducing the pandemic viral load through important biological inhibition is of great utility and sustainability.

These observations establish excellent conditions for the development of effective preventions and therapies.

CH . I . S . S . S.R.L.

Sede legale Piazza San Pietro in Vincoli 10 – 00184 Roma (RM)
Sede operativa Via Flaminia Ternana, 446 - 05035 Narni (TR)
Unità locale Via Giovanni Durando 38 – 20158 Milano (MI)

info@chiss.it - ww.chiss.it



Bibliography

- Azkur, A. K. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy*, doi:10.1111/all.14364 (2020).
- Perez, L. Acute phase protein response to viral infection and vaccination. *Arch Biochem Biophys* 671, 196-202, doi:10.1016/j.abb.2019.07.013 (2019).
- Wan, S. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol* 92, 797-806, doi:10.1002/jmv.25783 (2020).
- Lin, J. X. & Leonard, W. J. Fine-Tuning Cytokine Signals. *Annu Rev Immunol* 37, 295-324, doi:10.1146/annurev-immunol-042718-041447 (2019).
- Ramos-Casals, M., Brito-Zeron, P., Lopez-Guillermo, A., Khamashta, M. A. & Bosch, X. Adult haemophagocytic syndrome. *Lancet* 383, 1503-1516, doi:10.1016/S0140-6736(13)61048-X (2014).
- Seguin, A., Galicier, L., Boutboul, D., Lemiale, V. & Azoulay, E. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. *Chest* 149, 1294-1301, doi:10.1016/j.chest.2015.11.004 (2016).
- Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 46, 846-848, doi:10.1007/s00134-020-05991-x (2020).
- Xiong, Y. et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect* 9, 761-770, doi:10.1080/22221751.2020.1747363 (2020).
- O'Brien, T. R. et al. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19. *Clin Infect Dis*, doi:10.1093/cid/ciaa453 (2020).
- Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. & Huang, C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res* 179, 104811, doi:10.1016/j.antiviral.2020.104811 (2020).
- Klinkhammer, J. et al. IFN-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. *Elife* 7, doi:10.7554/eLife.33354 (2018).
- Ziegler, C. G. K. et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* 181, 1016-1035 e1019, doi:10.1016/j.cell.2020.04.035 (2020).
- Braun, E. & Sauter, D. Furin-mediated protein processing in infectious diseases and cancer. *Clin Transl Immunology* 8, e1073, doi:10.1002/cti2.1073 (2019).
- Lin, M. et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. *BMC Med Genet* 4, 9, doi:10.1186/1471-2350-4-9 (2003).
- Nguyen, A. et al. Human leukocyte antigen susceptibility map for SARS-CoV-2. *J Virol*, doi:10.1128/JVI.00510-20 (2020).
- Giamarellos-Bourboulis, E. J. et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* 27, 992-1000 e1003, doi:10.1016/j.chom.2020.04.009 (2020).
- Ohno, Y. et al. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells. *Cancer Immunol Immunother* 65, 193-204, doi:10.1007/s00262-015-1791-4 (2016).
- Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*, doi:10.1016/j.cell.2020.05.015 (2020).
- Zhang, Y. et al. Protective humoral immunity in SARS-CoV-2 infected pediatric patients. *Cell Mol Immunol*, doi:10.1038/s41423-020-0438-3 (2020).
- Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* 368, 1274-1278, doi:10.1126/science.abc2241 (2020).
- Wang, F. et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. *J Infect Dis* 221, 1762-1769, doi:10.1093/infdis/jiaa150 (2020).
- Wang, X. et al. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. *Cell Mol Immunol*, doi:10.1038/s41423-020-0424-9 (2020).
- Li, Y. X. et al. [Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19]. *Zhonghua Nei Ke Za Zhi* 59, 372-374, doi:10.3760/cma.j.cn112138-20200221-00114 (2020).
- Du, Y. et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. *Am J Respir Crit Care Med* 201, 1372-1379, doi:10.1164/rccm.202003-0543OC (2020).
- Barton, L. M., Duval, E. J., Stroberg, E., Ghosh, S. & Mukhopadhyay, S. COVID-19 Autopsies, Oklahoma, USA. *Am J Clin Pathol* 153, 725-733, doi:10.1093/ajcp/aqaa062 (2020).
- [Agg. 16/09/2020] Dogan, M. et al. Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. *medRxiv* 2020.07.07.20148106 (2020) doi:10.1101/2020.07.07.20148106.
- [Agg. 16/09/2020] Guo, X. et al. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies. *Front. Immunol.* 11, (2020). doi: 10.3389/fimmu.2020.01936.

CH. I. S. S. S.R.L.

info@chiss.it - ww.chiss.it

Sede legale Piazza San Pietro in Vincoli 10 – 00184 Roma (RM)
Sede operativa Via Flaminia Ternana, 446 - 05035 Narni (TR)
Unità locale Via Giovanni Durando 38 – 20158 Milano (MI)